PCIB — PCI Biotech Holding ASA Share Price
0.000.00%
Last trade - 00:00- NOK46.66m
- NOK16.60m
- NOK2.99m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.46 | ||
| Price to Tang. Book | 1.46 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.78 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -55.57% | ||
| Return on Equity | -40.61% | ||
| Operating Margin | -296.63% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | NOKm | 9.39 | 7.37 | 6.27 | 4.75 | 2.99 | n/a | n/a | -20.78% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PCI Biotech Holding ASA is a cancer focused biopharmaceutical company based in Norway. The Company is developing therapeutic products based on its photochemical internalisation (PCI) technology. PCI Biotech’s product is the photosensitiser fimaporfin (Amphinex). The PCI technology can enhance the effect of anticancer drugs by targeted, light-directed drug delivery into cancer cells, and can also be used as a platform that may both potentiate the effect of vaccines and enable macromolecules to reach intracellular targets. The PCI technology platform consists of two elements: a small molecule photosensitiser (named fimaporfin) and a light source. The primary aim of PCI is to introduce drug molecules or macromolecules into the cytosol of the target cells. It is this drug or macromolecule that gives the biological effect in a PCI treatment, and the intended biological effect may range from cell killing, through modification of gene expression to enhanced antigen presentation.
Directors
- Hans Bohn CHM (61)
- Per Walday CEO (56)
- Ronny Skuggedal CFO (40)
- Anders Hogset CSO (62)
- Hans Olivecrona OTH
- Hilde Furberg DRC (63)
- Christina Herder DRC (58)
- Andrew Hughes DRC
- Lars Viksmoen DRC (72)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- March 19th, 2007
- Public Since
- June 18th, 2008
- No. of Employees
- 7
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Oslo Stock Exchange
- Shares in Issue
- 37,326,390
- Address
- Ullernchauseen 64, OSLO, 0379
- Web
- https://www.pcibiotech.no/
- Phone
- +47 67115400
- Contact
- Ronny Skuggedal
- Auditors
- Ernst & Young AS
Upcoming Events for PCIB
PCI Biotech Holding ASA Annual Shareholders Meeting
Similar to PCIB
Arcticzymes Technologies ASA
Oslo Stock Exchange
Bergenbio ASA
Oslo Stock Exchange
Circio Holding ASA
Oslo Stock Exchange
Exact Therapeutics AS
Oslo Stock Exchange
Lifecare ASA
Oslo Stock Exchange
FAQ
What is the PCI Biotech Holding ASA share price?
As of Today at 21:34 UTC, shares in PCI Biotech Holding ASA are trading at NOK1.25. This share price information is delayed by 15 minutes.
How has the PCI Biotech Holding ASA share price performed this year?
Shares in PCI Biotech Holding ASA last closed at NOK1.25 and the price had moved by -42.87% over the past 365 days. In terms of relative price strength the PCI Biotech Holding ASA share price has underperformed the FTSE Global All Cap Index by -48.82% over the past year.
What are the analyst and broker recommendations for PCI Biotech Holding ASA?
The overall consensus recommendation for PCI Biotech Holding ASA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the PCI Biotech Holding ASA dividend yield?
PCI Biotech Holding ASA does not currently pay a dividend.
Does PCI Biotech Holding ASA pay a dividend?
PCI Biotech Holding ASA does not currently pay a dividend.
When does PCI Biotech Holding ASA next pay dividends?
PCI Biotech Holding ASA does not currently pay a dividend.
How do I buy PCI Biotech Holding ASA shares?
To buy shares in PCI Biotech Holding ASA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of PCI Biotech Holding ASA?
As of the previous close price of NOK1.25, shares in PCI Biotech Holding ASA had a market capitalisation of NOK46.66m.
Where are PCI Biotech Holding ASA shares listed?
Here are the trading details for PCI Biotech Holding ASA:
- Country of listing: Norway
- Exchange: OSL
- Ticker Symbol: PCIB
What kind of share is PCI Biotech Holding ASA?
Based on an overall assessment of its quality, value and momentum PCI Biotech Holding ASA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a PCI Biotech Holding ASA share price forecast for 2025?
The analyst consensus target price for shares in PCI Biotech Holding ASA is NOK24.00. That is 1820% above the last closing price of NOK1.25.
Analysts covering PCI Biotech Holding ASA currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the PCI Biotech Holding ASA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like PCI Biotech Holding ASA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -28.31%.
As of the last closing price of NOK1.25, shares in PCI Biotech Holding ASA were trading -25.96% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the PCI Biotech Holding ASA PE Ratio?
The PCI Biotech Holding ASA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at NOK1.25.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of PCI Biotech Holding ASA?
PCI Biotech Holding ASA's management team is headed by:
- Hans Bohn - CHM
- Per Walday - CEO
- Ronny Skuggedal - CFO
- Anders Hogset - CSO
- Hans Olivecrona - OTH
- Hilde Furberg - DRC
- Christina Herder - DRC
- Andrew Hughes - DRC
- Lars Viksmoen - DRC